Evidence map›Paper›PMID 28399475›Full record

ArticleDrug and alcohol dependence2017

Everyday functional ability in HIV and methamphetamine dependence.

Arpi Minassian, Brook L Henry, Jennifer E Iudicello, Erin E Morgan, Scott L Letendre, Robert K Heaton, William Perry, Translational Methamphetamine AIDS Research Center

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Both HIV and Tat expression decrease prepulse inhibition with further impairment by methamphetamine.Progress in neuro-psychopharmacology & biological psychiatry · 2021
    Article
  8. HIV Neuropathogenesis in the Presence of a Disrupted Dopamine System.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arpi MinassianDepartment of Psychiatry, University of California San Diego, La Jolla, CA, United States; Center of Excellence for Stress and Mental Health (CESAMH), Veteran's Administration, San Diego, CA, United States. Electronic address: aminassian@ucsd.edu.
Brook L HenryDepartment of Psychiatry, University of California San Diego, La Jolla, CA, United States.
Jennifer E IudicelloDepartment of Psychiatry, University of California San Diego, La Jolla, CA, United States.
Erin E MorganDepartment of Psychiatry, University of California San Diego, La Jolla, CA, United States.
Scott L LetendreDepartment of Medicine, University of California San Diego, La Jolla, CA, United States.
Robert K HeatonDepartment of Psychiatry, University of California San Diego, La Jolla, CA, United States.
William PerryDepartment of Psychiatry, University of California San Diego, La Jolla, CA, United States.
Translational Methamphetamine AIDS Research Center

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Translational Methamphetamine AIDS Research Center (TMARC)P50DA026306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GRANT, IGOR · 2009 to 2018
$33.9M
Biomarkers of Blood Brain Barrier Injury in Methamphetamine Use and HIV DiseaseK23DA037793 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IUDICELLO, JENNIFER E · 2014 to 2018
$915k
NIAID NIH HHS P30 AI036214NIDA NIH HHS K23 DA037793NIDA NIH HHS P50 DA026306
6 · The paper itself

Abstract

backgroundMethamphetamine (METH) use is a risk factor for the transmission of HIV. Each is associated with neurocognitive impairment and subsequent problems in everyday functioning, yet additive effects of HIV and METH are not consistently observed. This study used the UCSD Performance-Based Skills Assessment (UPSA-2) to assess whether METH use disorder and HIV together resulted in poorer functional outcome than either condition alone.

methodParticipants in the Translational Methamphetamine AIDS Research Center (TMARC) cohort were stratified based upon HIV infection and METH use disorder: HIV-/METH- (n=49), HIV-/METH+ (n=48), HIV+/METH- (n=37), and HIV+/METH+ (n=38). They were administered the UPSA-2 which measures abilities in six domains of everyday functioning. Main effects and interactions of HIV and METH were examined, as were relationships between UPSA-2 scores and disease characteristics.

resultsSignificant HIV-by-METH interactions were observed for the UPSA-2 total score and Comprehension/Planning and Financial subscales such that METH was associated with lower scores in HIV- participants but not HIV+ participants. METH was associated with lower scores on the Communications subscale. All three risk groups had lower scores than HIV-/METH- participants. Recency and frequency of METH use were associated with lower scores. Lower Medication Management scores were related to lower nadir CD4 counts.

conclusionsMETH use disorder and HIV each impair functional performance, but there is no additive effect when the two conditions occur together. The neurocognitive sequelae of combined HIV infection and METH use are complex and warrant further study, as do the potential effects of compensatory strategies and other factors.

Indexed as

Activities of Daily LivingAdolescentAdultAgedAmphetamine-Related DisordersCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedYoung AdultCognitionEveryday functioningHIVMethamphetamineUPSA

Identifiers

PMID28399475
PMCPMC5603270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.